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1. Introduction
Nutrition in hemodialysis is very important in decreasing complications and improving
quality life of patients. Nutrition program on patients with chronic renal failure on dialysis
plays an important role in the process of treatment.
The purposes of medical nutrition therapy in dialysis patients are to promote the nutrition to
correct patients’ appetite, to correct systemic complications composed by the loss of nephrons
in progress, to reduce of protein catabolism to the lowest level, to relieve or prevent the cardio‐
vascular, cerebrovascular, peripheral vascular diseases formation, to prevent increasing fluid
and electrolyte disorders, to reduce uremic symptoms such as itching, nausea, vomiting, loss of
appetite and to ensure optimum nutrition. In addition, medical nutrition helps to avoid high-
potassium and sodium from the diet, to prevent pulmonary edema, hypertension and heart
failure, to prevent renal osteodystrophy keeping the consumption of calcium and phosphorus
under control, to prevent protein energy malnutrition with saving patients' food consumption
and detecting nutritional status with methods such anthropometric measurements, laboratory
findings, subjective global assessment (SGA) ( Cianciaruso 1995, Kopple 2004, Mahan 2012).
Negative changes (hyperkalemia, hiperfosfotemi, peripheral and pulmonary edema) in fluid-
electrolyte balance occur in patients who do not comply to the diet.
In this chapter, assessment of nutritional status in hemodialysis patients and preparation of
individual dietary training programs for patients will be discussed.
2. Assesment of the nutritional status
Regular assessment of nutritional status in hemodialysis patients is important and early de‐
tection of malnutrition can be helpful in improvıng this condition ( Fouque 2003).
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The results of studies indicate that hemodialysis patients are at risk of malnutrition. The
evaluation methods used in the nutritional status showed that 18-75% prevalence of malnu‐
trition in hemodialysis patients, malnutrition could cause a worse outcome and subsequent
mortality(Dwyer 2005). Chazot's study was assessed the nutritional status of twenty hemo‐
dialysis patients receiving hemodialysis treatment more than 20 years and was showed that
hemodialysis treatment caused to malnutrition the long period of time(Chazot 2001).
Malnutrition occurs depending on several factors in hemodialysis patients. Especially, there
is reduction of protein-energy intake because of inappropriate dietary restrictions, anorexia,
and taste alterations, promoting malnutrition in most patients entering dialysis (Lavılle
2000). Studies illustrate that there are two types of malnutrition in dialysis patients: The first
type is specified by uraemic syndrome and reduction in serum albumin levels due to de‐
creasing energy and protein intake. It should be provided improvement with adequate ener‐
gy and protein intake. The second type is associated with inflammation and atherosclerosis,
high cardiovascular mortalite(MIA Syndrome). Prominent features of this type, proinflam‐
matory cytokines, increased oxidative stress, increased protein catabolism, increased resting
energy expenditure, hypoalbuminemia (Stenvınkel 2000, Baltzan 1998). İn addition, malnu‐
trition due to poor nutrition, chronic volume overload congestive heart failure and systemic
hypertension, uraemic bone disease and extraskeletal metastatic calcification due to hyper‐
phosfotemia development are other adverse conditions encountered as a result of the diet
incompatibility.
In general, there are catabolic and inflammatory situation in patients with end-stage. Pa‐
tients  receiving  dialysis  treatment  are  seen  in  tissue  loss  in  the  course  of  time.  At  the
start of dialysis treatment, having a high level adipocyte tissue can be advantageous for
individuals. Dialysis patients who have excess body fat mass are being protected against
this  situation because of  more energy storage.  Recent  data shows that  patients  who are
overweight  or  obese  had  higher  rates  of  survival  than  normal  or  in  hemodialysis  pa‐
tients.  Low serum albumin level  (hypoalbuminemia)  revealed that  the  obese  are  less  in
HD patients. Reduction in mortality in overweight patients was reported as well as indi‐
cators of  nutritional  status of  overweight HD patients  was significantly higher than un‐
derweight  HD  patients  and  to  be  shorter  than  the  duration  of  hospital  stay.  (Glanton
2003, Guida 2004, Kalantar-Zadeh 2005)
Different methods are used in the evaluation of nutritional status in hemodialysis patients.
Biochemical, anthropometric measurements, nitrogen and energy balance techniques, re‐
cord of food intake, subjective global assessment, bioimpedance analysis (BIA), Dual-Energy
X-ray Absorptiometry (DEXA), creatinine kinetics, neutron activation analysis and nuclear
magnetic resonance spectrometry and serum markers: albumin, pre-albumin, insulin-like
growth factor-1 (IGF-1) and transferrin; main proteins of the acute phase (C-reactive protein
(CRP), serum amyloid A), secondary proteins of the acute phase (fibrinogen, ferritin, com‐
plement), cytokines (interleukin-6 (IL-6), tumour necrosis factor) are used to assess the nutri‐
tional status of patients with chronic renal failure (Basile 2003).
Some studies (Beddhu 2002, Panichi 2006) describe hypoalbuminemia in HD patients as a
strong indicator for mortality and morbidity. As a result of malnutrition, albumin synthesis
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decreases and develops hypoalbuminemia. In fact, the serum albumin level is a powerful
way directly correlated with dietary protein, but recent literature emphasizes that the effect
of serum albumin concentration on the inflammatory response. Albumin is a negative acute
phase protein, except nutritional status, and its synthesis is supressed during inflammation.
For this reason, there are limitations in the use of serum albumin level in order to assess the
nutritional status of patients due to be affected by malnutrition and inflammatory reactions
(Santos 2003). Indeed, because of longer half life, it cannot be a sensitive indicator for nutri‐
tional therapy. In studies, significant negative correlation was found between prealbumin
and CRP (Kaysen 1995, Owen 1998, Sathishbabu 2012). Prealbumin is a negative marker of
inflammation level that correlates positively and significantly with other nutritional markers
in ESRD patients on hemodialysis (Sathishbabu 2012). Because of the shorter half life of pre‐
albumin, many authors consider prealbumin to be a better marker of nutrition than serum
albumin (Mittman 2001, Kalantar-Zadeh 2003). That is considered one of the indicators of
uremic malnutrition less than 29mg/dl of serum prealbumin levels in patients on dialysis,
serial measurements are recommended in the evaluation of nutritional status (Pupim 2004).
Serum creatinine concentration (less than 10 mg/dl) should be evaluated for PEM and skele‐
tal muscle wasting, because it indicates reduced dietary protein intake and skeletal muscle
mass(Janardhan 2011).
Subjective Global Assessment (SGA) is often preferred by experts to assess the nutritional
status in chronic dialysis patients as relatively quick, easy, and cheaper than other methods
(Mutsert 2009). İt is important that SGA was proposed by the National Kidney Foundation
(NKF) Kidney Disease/Dialysis Outcomes and Quality Initiative (K/DOQI) for nutritional as‐
sessment in the adult dialysis patients(K/DOQI 2000).
Subjective  Global  Assessment  (SGA)  reveals  that  there  are  seven  components  to  assess
nutritional  status;  two components  related to physical  examination (indicator  of  fat  and
muscle  loss  and  nutritional  status-associated  with  changes  in  fluid  balance)  and  five
components of medical history (weight change, diet, gastrointestinal symptoms, function‐
al capacity, disease and nutrition relationship needs) ( Steiber 2004). While SGA scoring
points are given in each section of 1-7 and are categorized as 1-2 points (bad), 3-5 points
(moderate), 6-7 points (normal). If it is received from this SGA most 6 or 7 points refers
mild  malnutrition.  Most  of  3,  4  or  5  points  show  moderate  malnutrition.  Most  of  the
findings of sections 1 or 2 points received are recognized as marked malnutrition and se‐
vere  malnutrition  (Janardhan 2011).  European Best  Practice  Guidelines  (EBPG)  on diag‐
nosis  and monitoring of  malnutrition proposed that  the SGA can be used to  determine
malnutrition in hemodialysis patients (Fouque 2007).
Nutritional history and dietary record provide information about nutrition of patients and
determine for malnutrition development at risk whether or not. Because of record of food
intake is taken long-term, bored patients may cause to give false information. Therefore, re‐
cord of food intake 3-day to get more accurate for patients (Kalantar-Zadeh 2003).
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3. Energy
Enough energy should be taken for the effective use of dietary protein and the protection of
the nutrients stores of body. Energy metabolism is impaired and is composed of negative
energy balance because of disrupted cellular energy metabolism in hemodialysis patients
(Mak 2011). Therefore, to consume enough energy identified by the daily energy require‐
ments of ESRD patients provides a positive nitrogen balance and preventing tissue destruc‐
tion and protein catabolism.
The anorexia nervosa was often encountered in patients in the next few months from the
start of dialysis therapy. This is because, even though dramatic changes in their lives, psy‐
chological conditions, can not be adapted to a new and restricted diet. It has been reported if
protein and energy intake are not increased in these patients, lost energy is stored with mus‐
cle mass of patients, and the amount of body fat is decreased (Fouque 2003). The studies
have suggested that the dietary energy failure is more on dialysis treatment days than non
dialysis treatment days (Burrowes 2003, Rao 2000). In a prospective multicenter clinical trial
that included 1901 participants of the Hemodialysis Study, dietary energy intake was 1.02
kcal/kg/day less on dialysis treatment days than on nondialysis treatment days. (Burrowes
2003, Stark 2011).
Some studies indicated that energy intake was low in hemodialysis patients. Poor appetite
and hypermetabolism fairly reduce food intake in hemodialysis patients (O‘Keefe 2002, Na‐
kao 2003, Morais 2005, İkizler 2002, Pumpkin 2002). When the recommended energy re‐
quirements compared with consumed amounts, it is concluded that energy intake is
inadequate in 90% of patients (Rocco 2002)
When energy intake of hemodialysis patients was 32-38 kcal/kg/day, have not been reported
any increasing or decreasing in nitrogen balance and anthropometric parameters, and devel‐
oping a negative or a positive energy balance. (Kopple 2004).
Studies demonstrated that low-energy and with low protein diet cause weight loss and mal‐
nutrition in patients. For these reasons, sedentary, non-obese dialysis patients's require‐
ments of energy coming from all sources should be determined, according to NKF-DOQI,
ESPEN and EDTNA-ERCA 2002; respectively, 35 cal/kg/day (under the age of 60), 30-35
cal/kg/day(over the age of 60); 35 cal/kg/day and 30-35 cal/kg (ideal body weight)/day. (Kop‐
ple 2001, Kopple 2004, Cano 2006, Fouque 2003). In some studies, it was shown that hemo‐
dialysis patients should receive daily energy as 30-40 kcal/kg (Kalantar-Zadeh 2003,
Stenvinkel 2000).
4. Protein
Protein requirement increases due to the dialysate losses and catabolism in hemodialysis pa‐
tients. In research, it is emphasized that the inadequate protein intake increases mortality
(Ohkawa 2004).
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Raj et al's study showed that hemodialysis increases both protein synthesis and degradation.
The net effect of hemodialysis is loss of nitrogen in skeletal muscle. Protein synthesis and
degradation increases by 50-100% of normal values. Hemodialysis causes to increase in ca‐
tabolic indicators such as interleukin-1 (IL-1), interleukin-6 (IL-6) and tumor necrosis factor
alpha (TNF-α). This increasing in the production of cytokines causes in protein degradation.
Reasons for increased protein requirement; amino acid losses into the dialysate, increased
protein catabolism, metabolic and hormonal changes(Raj 2007).
There are 0.2-0.3 g/kg or 6-8 g/day of protein, amino acids (aa) and peptide losses with the
dialysis fluid during hemodialysis. Protein catabolism increases with these losses due to
metabolic disorders. The lost in amino acids needs to be replaced to avoid negative nitrogen
balance. According to "National Kidney Foundation Dialysis Outcome Quality Initative
(NKF-DOQI)" and studies by other investigators to compensate for residual renal losses, di‐
etary protein should be adjusted at least 1.2 g/kg/day in hemodialysis patients as indicated
(Kopple 2001, Mahan 2012, Kalantar-Zadeh 2003, Locatelli 2005).
According to ESPEN, adjusted diet protein should be consumed as 1.1-1.2 g / kg / day and
should be high in the biological value (of animal origin) of 50 % protein in hemodialysis pa‐
tients (Mehrotra 2001, Karalis 2002, Cano 2006). Furthermore, the amount of protein of the
patient's diet is determined by considering the state of hydration adjusted body weight, glo‐
merular filtration rate and with the course of illness (Nissenson 2008). To determine the ade‐
quacy of protein intake in dialysis patients, a good evaluation parameter is BUN value
under 120 mg. When 1.2 g / kg / day protein intake, it was indicated protein catabolic rate is
associated with low morbidity, provided adequate control of blood urea concentration, im‐
proved the nutritional parameters (anthropometric measurements) and biochemical find‐
ings (blood albumin, total protein, blood, blood cholesterol, etc.), provided a positive
nitrogen balance in dialysis patients (Bergstrom 1993, Amanda 2010).
However, it is required that adequate caloric intake prevent the use of protein as an energy
source with gluconeogenessis. Otherwise, a positive nitrogen balance can not be provided in
spite of high protein intake. When patients were given a low protein diet, should be fol‐
lowed adequate energy intakes and adequate phosphorus intakes of patients to ensure opti‐
mal nutrition, and to prevent malnutrition (Locatelli 2005, Gribotto 2012).
Metabolic acidosis in hemodialysis patients increases protein catabolism, the branched-
chain amino acid degradation and muscle glutamine release. Amino acids and glutamine
metabolism allow the formation of ammonium and bicarbonate excretion. Changes at
branched-chain amino acids levels of muscle and plasma occur in hemodialysis patients. As
a result of hemodialysis treatment, plasma valine, muscle valine, plasma leucine are low,
muscle leucine, plasma isoleucine, muscle isoleucine are normally observed (Cano, Fouque
2006). Branched-chain amino acids play a regulatory role against chronic acidosis. After
acidosis subside is given a support and enriched with branched-chain amino acids and va‐
line during hemodialysis, branched-chain amino acids level of plasma and intracellular are
enhanced. (Raj 2000).
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Branched-chain amino acids improve appetite in hemodialysis patients. 6.6-15.7 g daily in‐
take of essential amino acids in hemodialysis patients corrected the their nutritional parame‐
ters. In patients who underwent 12 g oral branched-chain amino acid a day showed
improvement in protein and energy purchases in one month, in the anthropometric meas‐
urements six months later. Consantrations of albumin increased 3:31 g / dL to 3.93 g / dL.
(Cano, Fouque 2006) According to Raj, although amino acid repletion increased in muscle
protein synthesis, no decrease in muscle protein breakdown during HD treatment was ob‐
served (Raj 2007)
There is a dynamic effect of animal protein (such as egg, dairy etc.) on renal function in
short-term clinical trials. But long-term effects on the normal kidney functions are still un‐
known. There are mechanisms shown to reveal the different effects of animal and vegetable
proteins on renal function including differences in hormones, protein metabolism and inter‐
action with micronutrients. Healthy individuals with normal renal function, long-term con‐
sumed high-protein diet (whether of animal protein or vegetable protein) may cause kidney
damage and accelerate chronic renal failure. However, long term studies are necessary to
determine the different effect of the consumption of animal or vegetable protein diet on re‐
nal functions (Bernstein 2007).
5. Carbohydrate
Carbohydrate intake requires enough energy and to maintain reserve protein that can be
used for the synthesis protein of tissue.
When dialysis fluid not containing glucose is used for 4 hours, 28 g glucose is lost in hemo‐
dialysis. However, when 11 mmol / L glucose was added to the dialysis fluid, the patient
gained approximately 23 g of glucose. When glucose is removed by dialysis in the extracel‐
lular fluid, loss of the glucose is completed with absorbed carbohydrates, destruction of liv‐
er glycogen, and glyconeogenesis in order to avoid symptomatic hypoglycemia. Then,
increased protein breakdown and urea synthesis begin. Glucose-free dialysis is reduced pyr‐
uvate. Pyruvate does not change with glucose dialysis. Glyconeogenesis may be stimulated
with glucose-free dialysis. However, there are negative effects of glucose intake such as hy‐
perglycemia, hyperinsulinemia, hyperlipidemia, obesity etc(Lindholm 1998).
Deterioration of glucose metabolism and insulin resistance develops in chronic renal failure.
This situation results in rising levels of glucose and urea when coupled with increased hep‐
atic gluconeogenesis. Insulin metabolism in uremia shows severe abnormalities. Basal insu‐
lin secretion is reduced and receives limited response to glucose infusion (Kopple 2004).
In one study, it was observed occurrence of the insulin resistance impaired, muscle glucose
uptake and nonoxidative glucose metabolism, in the presence of chronic uremia, but recov‐
ered after dialysis (Foss 1996).
Uric acid is generated during fructose metabolism. Serum uric acid levels have been found
to correlate with fructose intake. High serum uric acid was associated with hypertension, in‐
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flammation, chronic kidney disease and the intake of fructose and added sugars (Feig 2008,
Brymora 2012). But fruits containing fructose have some beneficial substances such as anti‐
oxidants. Therefore, it is possible that fructose intake from natural fruits with regular diet.
(Jalal 2010, Brymora 2012).
Carbohydrate from the diet should be higher to provide enough energy, to protect the back‐
up protein to be used for tissue protein synthesis, to cover the energy deficit. It should pro‐
vided 60-65% of daily energy from carbohydrates (Kopple 2004). Most patients have
difficulty in meeting energy needs with low protein diets. For this reason, the energy gap
can be covered by glucose polymers (starch), sugar, simple sugars, pure carbohydrate sour‐
ces. Patients with diabetes should avoid concentrated sweets (Mahan 2012).
6. Lipids
Recent evidence suggests that protein calorie malnutrition often begins incipiently when the
glomerular filtration rate (GFR) is about 28 to 35 mL/min/1.73 m2 or even higher (Kopple
1994) and continues to fall gradually as the GFR decreases below these values (Laville 2000).
Reduced quantity of GFH causes a significant increase in plasma lipid levels(Liu 2004). Es‐
pecially, hyperlipidemia consists when creatinine clearance is below 50 ml/min in patients.
In Rutkowski's study, accumulation of triglycerides-rich lipoproteins was associated with
increased lipogenetik gene expression of enzymes and the high quantity triglycerides pro‐
duction by renal deficiency (Rutkowski 2003, Liu 2004).
Usually, there are hypertriglyceridemia and hyperlipidemia in hemodialysis patients. Low-
density lipoprotein (LDL) and very low density lipoprotein (VLDL) are high concentration,
high density lipoprotein (HDL) cholesterol concentration is low. The main reason of hyper‐
triglyceridemia is the lack of removal of triglycerides from the circulation (Kwan 2007, Lac‐
quaniti 2010). In these patients, it has been reported decreased lipoprotein lipase, hepatic
lipase enzyme activity.
Generally it is known to decrease in carnitine storages in hemodialysis patients with malnu‐
trition. In addition, carnitine leaves from the extracellular fluid during dialysis therapy and
this situation causes a sudden drop in serum level of carnitine. Carnitine deficiency is
caused by deterioration of long-chain fatty acid oxidation and thus deficiency of energy(Ma‐
tera 2003, Flanagan 2010). İt was determined to put on 750 mg/day carnitine supplementa‐
tion in diet of hemodialysis patients, reduced the level of plasma TG and LDL cholesterol
and increased HDL cholesterol levels(Naini 2012).
Hyperlipidemia develops in a large part of dialysis patients, the amount of fat in the diet
should not be higher. Saturated fat content of the diet should be reduced and unsaturated
fat content should be increased (Vaziri 2006).
Hyperlipidemia progresses in the majority of patients with CKD; therefore, content of fat in
the diet should not be high. Total energy from fat should not exceed 25% to 30. İt should be
reduced saturated fat content of the diet and increased unsaturated fat content.
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It  is  recommended reducing  saturated  fat  intake  (total  energy  <7%)  and  cholesterol  in‐
take (<200 mg /  day).  Total  fat  content of  the diet  should be between 25-35% of energy
and monounsaturated fatty acids 15-20% of total energy, polyunsaturated fatty acids 10%
of  total  energy  of  the  diet  (Nissesson  2008).  Recommended  foods  for  patients  with  a
high biological  value such as  meat,  eggs  contain  high cholesterol.  Therefore  assessment
of serum cholesterol levels should be specific for each patient.  If  patients have hypertri‐
glyceridemia  and  high  cholesterol,  regulation  dietary  fat  content,  weight  control,  in‐
creased  physical  activity,  reducing  the  use  of  hypertonic  solution,  restriction  of  simple
sugars of dietary intake are recommended.
Signs  and  symptoms  of  deficiency  of  essential  fatty  acids  such  as  dry  and  itchy  skin,
hair  loss,  abnormal  prostaglandin  synthesis  are  observed  in  dialysis  patients.  EPA  and
DHA  which  replace  arachidonic  acid  in  cell  membrane  and  prevents  the  formation  of
pro-inflammatory  compounds are  part  of  linolenic  acid  in  fish  oil  (n-3  fatty  acids).  Ac‐
cording to FDA, intake of n-3 fatty acid with food supplements should not exceed 3 g /
day (Vergili-Nelsen JM 2003).
The studies were reported that omega-3 food supplementation reduced levels of triglyceride
(Bouzidi 2010, Skulas-Ray 2008), LDL cholesterol and CRP (Saifullah 2007), as well as Ome‐
ga-6 / omega-3 polyunsaturated fatty acids ratio was important for inflammation and mor‐
tality rate in hemodialysis patients(Noori 2011, Daud 2012).
7. Water and electrolytes
The fluid adjustment should be made according to edema and dehydration in the patient. In
hemodialysis patients, if conditions such as swelling of the eyes, hands or feet, fluid weight
gain, shortness of breath, increased blood pressure or tachycardia are observed, fluid con‐
sumption should be restricted (Hegel 1992, Saran 2003). Hemodialysis patients should re‐
duce fluid intake and should limit food consumption such as tea, coffee, soda, water, fruit
juices, ice cream, sherbet, gelatin, soups and heavy sauces.
Dietitians, especially renal dietitians, are most often cited as the trusted source on providing
information on fluid management and delivering dietary advice (Smith 2010).Research
about fluid balance dietician indicates that it is important to teach patients how to deal with
thirst without drinking liquids. Proposals such as sucking on ice chips, cold sliced fruit, or
sour candies and using artificial saliva are recommended (Mahan 2012).
Controlling sodium and fluid intake are important components of the HD diet. Extracel‐
lular volume expansion is the main pathophysiologic determinant of hypertension in HD
patients. Water and sodium intake in hemodialysis patients are adjusted according to the
amount of urine, fluid balance and blood pressure. With hemodialysis, potassium restric‐
tion is often necessary, but the measure of restriction depends on residual renal function
(Stark 2011).
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Body weight gain during hemodialysis is recommended and should not exceed 1.5-2 kg. A
recommended daily amount of fluid of hemodialysis patients should be 500ml + the urinary
output in a day or around 1000-1500 ml. Sodium restriction should be based on the amount
of urine. A mild salt restriction as 3-4 g / day is sufficient in oliguric patients that have an
amount of urine totaling more than 1 liter per day. Anuric hemodialysis patients may con‐
sume up to 1 liter of liquid 1-1.5-2 g / daily of salt. If hypertension or heart failure is present,
salt and water restriction should be more monitored more delicately. Excess salt intake caus‐
es an increase for the feeling of thirst and liquid intake (Fouque 2003, Lindley 2009).
To reduce sodium intake in hemodialysis patients, olives, pickles, cured meats, garlic sauce,
soy sauce, canned foods, sausages, processed meats, ham, chips, pretzels and instant soups
should be removed from the diet. Different spices, such as vinegar and lemon, can be used
for consumption of unsalted foods or as a salt substitute.
Potassium levels are affected by hemodialysis therapy with the degree of residual renal
function and net tissue breakdown (e.g. due to infections) and acid-base status. In HD pa‐
tients, serum potassium concentrations may change to net intestinal potassium absorption
or excretion. An example of this change or excretion is diarrhea. Serum potassium is im‐
pressed by dietary potassium intake. It is thought this relationship is stronger when the po‐
tassium intake is very low or very high in diets of HD patients (Kaveh 2001, Noori 2010).
Potassium restriction is often required because hemodialysis patients are usually anuric.
Anuric HD patients are recommended to restrict their potassium intake to 1600-2000mg dai‐
ly. Hypokalemia may occur with symptoms such as severe vomiting, diarrhea, diuretic use,
due to the reduction of potassium. In this case, the potassium content of the diet should be
increased (Fouquo 2003).
When blood potassium levels in dialysis patients are high, treatment of the patient's diet
should be reviewed as a priority. The food consumption should be limited to reduce the in‐
take of potassium levels, such as milk, meat products, fruits, legumes, cereals, dried fruits
and vegetables,etc.
8. Vitamin and minerals
Some studies demonstrate vitamin and mineral supplements for the long-term hemodialysis
patients. Hemodialysis patients are potentially at risk of deficiency and excess of trace ele‐
ments (Inamoto 2003). Given that essential trace elements play key roles in multiple biologi‐
cal systems, including immunological defense against oxidation and infection. It has been
hypothesized that the increased morbidity and mortality seen in hemodialysis patients may
in part be due to the imbalance of trace elements that has not yet been recognized (D’Haese
1996, Coombes 2012).
In HD patients, there are many problems associated with the lack of food intake. Poor nutri‐
tion, restriction of foods that are rich in water-soluble vitamins, foods that are rich in potas‐
sium, metabolic disorders caused by uremia, infection and diseases such as gastrointestinal
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diseases or complications associated with reduced intake of foods are some of the possible
scenarios. The lack of foods containing vitamins leads to vitamin and deficiencies that could
cause of further possible complications in dialysis patients. (Mahan 2012).
In dialysis patients, B6, folic acid and vitamin C deficiencies have been observed (Coveney
2011). Vitamin B6 deficiencies, especially as it plays in amino acid utilization and lipid me‐
tabolism and maintains a critical role as a coenzyme, are very important to monitor closely.
Deficiencies in either folic acid, vitamin B6 or vitamin B12 can greatly affect to capacity of
the others to function properly (Wierzbicki 2007). This bond requires all to work in synchro‐
ny for optimum performance of the metabolic pathway. İf Vitamin B6 and folic acid supple‐
ments are not used in dialysis treatment, pyridoxine and folic acid may often reduce red
cells and plasma (Steiber 2011). In dialysis patients, an additional intake of vitamin B6 re‐
duces plasma cholesterol and triglyceride levels and additional intake of folic acid can re‐
duce the high levels of homocysteine, which has been determined to be a risk factor for
cardiovascular disease (Dumm 2003). Vitamin B6 and folic acid intake in HD patients are
higher than normal healthy subjects, and respectively, the recommended intake varied be‐
tween 1 mg and 10mg per day in most studies (Steiber 2011).
In addition, the loss of vitamin C has been observed in HD patients. Increasing vitamin C in
the diet to a recommended amount of 100-200 mg/daily was at once the standard suggestion
of mending this problem. However, the intake of higher doses of ascorbic acid was found to
possibly lead to the accumulation of oxalate, which is the metabolite of vitamin C. With oxa‐
late accumulation, formation of calcium oxalate stones in the kidneys, the accumulation of
calcium oxalate in internal organs and blood vessels, hypercalcemia and hiperoxalemia are
all symptoms (Moyad 2009). Recently, the daily requirement of vitamin C in patients under‐
going hemodialysis is suggested at 60-90 mg/daily (Kopple 2004). In addition, ascorbic acid
supplementations, are composed of iron overload. In uremic patients, it is recommended to
prevent resistance to erythropoietin. Vitamin C supplementation increased intestinal iron
absorption in these patients, which may reduce the incidences of iron deficiency anemia
(Handelman 2011).
Thiamine sources are whole grain and enriched bread and cereals, peas, beans, nuts, brown
rice, and meats. It is absent in rice and some cereal products. Thiamine nutritional value is
lost with cooking, polishing and purifying. Thiamine is not stored in the body and is excret‐
ed in the urine, because of a water-soluble vitamins (Steiber 2011). The addition of thiamin is
controversial among some experts. However, 30 mg thiamine has been shown to support
the improving of the activity of translocases red blood cells. Thiamine requirements should
be 1.5 mg / daily, when dialysis patients have operations, infections have a high risk of de‐
veloping, convulsions of the neurological symptoms can occur and large quantities of glu‐
cose adds to the diet(Fattal-Valevski 2011, Fouque 2003).
25 (OH) D3 levels of dialysis patients are known to be lower than the normal population.
Treating vitamin D deficiencies shows the important contributions and progressions to‐
wards enhancing the quality of life with dialysis patients (Cheng 2007). The studies showed
25(OH)D3 levels significantly lower than 15 ng / mL (37 nmol / L) in patients. The lowest
value of vitamin D is accompanied by high levels of secondary hyperparathyroidism (Gha‐
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zali 1999). There are several reasons for this a) The patient should have a specific catered di‐
et, but this diet may incude the reduction of the intake of vitamin D foods (milk, fish, cream,
butter, etc.). b) The endogenous synthesis of vitamin D3 decreases in individuals over 60
years, due to increased melanin and reduced contact with sunlight in the skin (Godar 2012,
Holick 1987). c) Urinary path 25 (OH) D3 and vitamin D binding protein loss is high (Saha
1994). d) The decrease of glomerular filtration rate (GFR)( Kawashima 1995, Thadhani 2012).
Hemodialysis  treatment  does  not  provide  a  change  for  vitamin  A  levels.  B-carotene,
ubiquinol, and laykopen levels were lower in patients that didn't have renal failure. The
intake of dietary vitamin A should not exceed the RDA in HD patients of 800-1000 mg/
day(Koople 2004).
İncreased oxidative stress and cardiovascular risks are associated with hemodialysis pa‐
tients. The antioxidant properties of vitamin E may be useful in preventing or reducing
these risks. HD patients are recommended 400 IU/Daily intake of vitamin E (Galli 2004,
Mann 2004, Kopple 2004).
Protein and phosphorus restriction,  loss of  appetite,  and vitamin D deficiencies increase
the need of calcium in HD patients.  Support of  calcium and control  of  serum phospho‐
rus levels,  by using calcium-containing phosphate-binding agents,  are  balanced simulta‐
neously  (Miller  2010).  Calcium acetate  or  calcium carbonate  are  effective  with  reducing
concentration  of  serum phosphorus,  simultaneously,  correcting  hypocalcemia  and nega‐
tive calcium balance (Isakova 2009, Miller 2010). However, the use of vitamin D and cal‐
cium  in  hemodialysis  patients  concluded  the  risk  for  severe  hypercalcemia  and  renal
osteodystrophy (Tilman 2009). Increasing calcium during treatment should be done care‐
fully.  As  a  result,  to  ensure  the  positive  balance  of  calcium  levels  in  dialysis  patients,
1000-1500 mg of calcium should be taken daily.
Lack of phosphorus excretion in the human body can be closely related to the glomerular
filtration rate. Even if a single nephron loses its function, it may result in the accumulation
of phosphorus in the plasma while showing an inability to the discharging of phosphorus
(Kopple 2004). When GFR decreased 120 mL / min to 25 mL / min, the accumulation of
phosphorus was observed very clearly in the plasma. In hemodialysis patients, the level of
serum phosphorus 2.5-4.5 mg / dL, and patients who have a glomerular filtration rate (GFR)
between 25 mL/min/1.73 m2 and 70 mL/min/1.73 m2, 8 mg/kg/d to 10 mg/kg/d of phospho‐
rus may be given with the 0.55 g/kg/d to 0.60 g/kg/d of protein. High biological value pro‐
tein sources including essential amino acids are rich foods from phosphorus, therefore there
are difficulties on the limitation of phosphorus. For this reason, the absorption of phospho‐
rus is prevented with the phosphorus binding agents from the outside. Egg white is a rich
source of high biological value protein have one of the lowest phosphorus-protein ratios and
is also deprived from cholesterol; therefore, it is a particularly healthy food source of protein
for patients on dialysis (Noori 2010). Whole eggs instead of egg whites, whole bread instead
of white bread, dried beans instead of peas and preferably fish (cod, tuna) that have a low
phosphorus / protein ratio, should be consumed to reduce dietary phosphorus intakes in di‐
alysis patients (Cupisti 2003). The active form of vitamin D is added in the treatment, this is
an important step in the control of serum parathyroid hormone activity (Steiber 20109).
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About 80% absorption of dietary phosphorus from the gastrointestinal tract requires the use
of phosphorus-binding agents (Locatelli 2002, Guarneri 2003, Noori 2010, Noori 2010). Nia‐
cin working with a different mechanism than phosphate binders, is helpful to lower phos‐
phate levels while causing a decrease transport of phosphate without interfering with the
sodium-phosphate pump in the GI lumen (Mahan 2012, Cheng 2006).
Patients with kidney disease are more difficult to assess whether there is sufficient amount
of trace elements in the body. Iron (Fe), calcium and zinc deficiencies are demonstrated in
dialysis patients. Frequently anemia is shown in dialysis patients due to an iron deficiency
(Tarng 1999, Vinay 2009). Because the amount of iron absorbed in the intestine is decreased,
severe blood loss can be a symptom. In addition, the formation of erythropoietin decreases
due to bone marrow suppression by urea (Mahan 2012). Adding iron is recommended after
assessing the patient's serum ferritin and iron levels (Rambod 2008). Intravenous iron thera‐
py can be applied to patients for the treatment of anemia. With this treatment, hemoglobin
was shown to be removable at 5-7 g / dL to 10 g / dL. Due to the fact that erythropoietin
therapy increases usage of iron, it is recommended for patients to take iron supplementa‐
tion.
Uremic  symptoms,  such  as  anorexia,  impaired  taste  sensation,  reduced  oxidative  stress
improved immune function and sexual dysfunction are associated with Zn deficiency in
HD patients. CRP is a sensitive marker of inflammatory activity; an association between
decreased plasma Zn concentrations with higher CRP levels in hemodialysis patients has
been noted (Guo 2010). Concentrations of serum Zn may affected from medications used
by  hemodialysis  patients  such  as  calcium  carbonate,  calcitriol  (Dashti-Khavidaki  2010),
aluminum phosphate-binders. For these reasons, Zn, Fe, magnesium (Mg) are needed, re‐
spectively, 15 mg / day, 10-18 mg / day, 200-300 mg / daily in dialysis patients (Fouque
2003). In addition, good sources of zinc are meat, poultry, nuts, and lentils and fortified
breakfast cereals (Rucker 2010).
Mild selenium deficiency also appears to increase susceptibility to oxidant stress (Klotz
2003, Rayman 2002), which may be especially relevant to HD patients in whom oxidative
stress is markedly increased (Stenvinkel 2003) and may contribute to accelerated atheroscle‐
rosis. Selenium deficiency may contribute to the risk of infection (Field 2002) and perhaps to
uremic cardiomyopathy, thus contributing to the increased risk of CVD in the HD popula‐
tion. The selenium content of grains and seeds is variable, and depends on the selenium con‐
tent of the soil and the form in which selenium is present (Rucker 2010). Selenium is also
present in some meats, seafood, and nuts (particularly brazil nuts); levels in these foods may
again be influenced by ambient soil levels (Rayman 2000). Some studies demonstrated oxi‐
dative stress and atherosclerosis is associated with selenium deficiency, because of its link to
infection and uremic cardiomyopathy. Selenium deficiency increases risk of cardiovascular
disease in HD patients(Fujishima 2011).
Recommended dietary nutrient intake for hemodialysis patients are shown below in Table 1
(Nissesson 2008, Rucker 2010, Fouque 2007).
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Macronutrients and Fiber
Dietary protein intake (DPI) • 1.2 g/kg/d for clinically stable patients
(at least 50% should be of high biological value)
Daily energy intake (DEI) • 35 kcal/kg/d if <60 years
• 30–35 kcal/kg/d if 60 years or older
Total fat 25–35% of total energy intake
Saturated fat <7% of total energy intake
Polyunsaturated fatty acids Up to 10% of total calories
Monounsaturated fatty acids Up to 20% of total calories
Carbohydrate Rest of calories (complex carbohydrates preferred)
Total fiber "/>20–25 g/d
Minerals and Water (Range of Intake)
Sodium 750–2000 mg/d
Potassium 2000-2750 mg/d
Phosphorus 800-1000 mg/d
Calcium <1000 mg/d
Magnesium 200–300 mg/d
Iron 10-18 mg/d
Zinc 15 mg/d
Selenyum 55 µq/d
Water Usually 750–1500 mL/d
Vitamins (Including Dietary Supplements)
Vitamin B1 (thiamin) 1.1–1.2 mg/d
Vitamin B2 (riboflavin) 1.1–1.3 mg/d
Pantothenic acid 5 mg/d
Biotin 30 μg/d
Niacin 14–16 mg/d
Vitamin B6 (pyridoxine) 10 mg/d
Vitamin B12 2.4 μg/d
Vitamin C 75–90 mg/d
Folic Acid 1–5 mg/d
Vitamin A 800-1000 µg/d
Vitamin D 1000-1500 IU
Vitamin E 400–800 IU
Table 1. Recommended Dietary Nutrient Intake for Hemodialysis Patients
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9. Conclusion
To evaluate the amount of food intake and food preference, the patient's diet history should
be taken. The patient's age, gender, social environment, economic, psychological, and educa‐
tional status and history of the disease should be considered due to nutrition effect. Also,
including weekends, during the 3-7 days whole foods is recorded by the patient along with
the amount. Daily intake of calories and nutrients of the patients are calculated with infor‐
mation from those records. In addition, laboratory values and SGA as a scoring tool are very
important for preparing a appropriate diet for HD patients.
The  hemodialysis  therapy  should  be  dealt  with  by  a  multidisciplinary  team,  as  recom‐
mended for other high risk populations (Morais 2005). A part of medical nutrition thera‐
py is  to  provide nutrition education and periodic  counseling by dietitians.  For  effective
intervention, dietitians should present a guide for educating HD patients about individu‐
al  nutritional  needs.  This  guide  should  provide  information  about  food  sources,  nu‐
trients  and  usage  exchange  food  lists.  Adapting  to  patients  requirements  of  intakes
should  be  based  on  their  laboratory  values.  Patients  may  be  predisposed  to  receiving
lower  than  recommended  amounts  of  energy  and  macro-nutrients  to  the  diet  and  pa‐
tients  who  received  information  or  counseling  about  their  diet  must  be  followed  up
closely by renal dietitians (Mahan 2012).
If a patient has diabetes, the control of blood sugar is required with a specialized diet thera‐
py. Due to high serum glucose levels, osmolality increases, water and potassium are pulled
out of cells. There are the relationship between glycemic control and survival of hemodialy‐
sis patients (Mahan 2012). Poor glycemic control causes to macrovascular complications and
generation of advanced glycation end products (AGEs)( Ricks 2012). The diet for diabetes
management can be modified for a patient on dialysis.
Recently, dialysis treatment is increasing in elderly patients with end-stage renal disease
(ESRD) (Tamura 2009). Elderly hemodialysis patients have some diseases such as ischemic
heart disease, diabetes mellitus, infectious diseases, bone fracture, cerebrovascular disease in
common with ESRD. Specific prescriptions should prepare for elderly dialysis patients such
as longer treatment time, nutritional support, and a personalized treatment schedule(Burns
2003). In addition, tube feeding and parenteral interventions may reinforce protein and en‐
ergy intake among patients with malnutrition and anorexia.
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